CHAC1 and nonpapillary renal cell carcinoma: Translational perspectives emphasize CHAC1’s clinical utility, encompassing its application as a dynamic biomarker for ccRCC risk stratification and disease staging, the development of CHAC1-targeted therapies including activators and microenvironment-modulating agents (e.g., exosomal miRNA inhibitors) to reverse chemoresistance, and rational combination strategies with androgen pathway inhibitors or immune checkpoint modulators.